# Extension Treatment Using EryDex System in Patients With AT Who Participated in the ATTeST-IEDAT-02-2015 Study

> **NCT03563053** · PHASE3 · TERMINATED · sponsor: **Quince Therapeutics S.p.A.** · enrollment: 104 (actual)

## Conditions studied

- Ataxia Telangiectasia
- Genetic Syndrome

## Interventions

- **COMBINATION_PRODUCT:** EryDex System

## Key facts

- **NCT ID:** NCT03563053
- **Lead sponsor:** Quince Therapeutics S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-06-12
- **Primary completion:** 2022-09-02
- **Final completion:** 2022-09-02
- **Target enrollment:** 104 (ACTUAL)
- **Why stopped:** terminated by sponsor
- **Last updated:** 2024-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03563053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03563053, "Extension Treatment Using EryDex System in Patients With AT Who Participated in the ATTeST-IEDAT-02-2015 Study". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03563053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*